ESPE Yearbook of Paediatric Endocrinology

Brief summary: This study examined glycemic control following treatment with once-weekly exenatide 2 mg (Bydureon, AstraZeneca) in youth with T2D which was not optimally controlled. At 24 weeks, exenatide was superior to placebo in lowering HbA1c (least squares mean change, −0.36% with exenatide vs. +0.49% with placebo), with a between-group difference of −0.85%.Comment: The story of the development of exenatide is fascinating. It starts with...

N Engl J Med 2019; 10.1056/NEJMoa1903822.DOI: 10.1056/NEJMoa1903822http://www.ncbi.nlm.nih.gov/pubmed/31034184Summary: In a double-blind, randomized, phase 3 trial, 135 overweight and obese adolescents, aged 10 to 17 years with T2DM, were randomly assigned to receive subcutaneous liraglutide (up to 1.8 mg per day) or placebo, bot...

The New England Journal of Medicine 2021;385(5):416-26. doi: 10.1056/NEJMoa2100165Brief Summary: This multicenter observational study assessed the cumulative incidence of diabetic complications in 500 adolescents with Type 2 diabetes (T2DM), followed from 2011 to 2020. After only 13 years from T2DM diagnosis, higher complication rates were observed than those reported for pediatric patients wit...